Nasdaq · Biotech stocks database
HCM (HUTCHMED (China) Limited) stock: $13.67, $2.38B market cap, $1.37B cash, $1.02B EV, $2.38B fully diluted market cap. Next expected readout: Oct-26. Lead program: HMPL-760 (Relapsed/Refractory Diffuse Large B-Cell Lymphoma), Phase 3. Data from Fully Diluted's biotech stocks database.
| Cash | $1,367.3M |
|---|---|
| Debt | $0.0M |
| Net cash | $1,367.3M |
| Enterprise value | $1,017.6M |
| Basic shares | 174.4M shares |
| Fully diluted shares | 174.5M shares |
| Fully diluted market cap | $2,384.9M |
| Cash per share | $7.84 |
Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Loading HCM daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Nov 12 - Dec 24 | HMPL-760 | Phase 1 | Healthy Participants | — |
| Jan 12 - Feb 23 | HMPL-306 | Phase 1 | Gliomas Harboring IDH1 and/or IDH2 Mutations | — |
| Nov 19 - Dec 31 | HMPL-506 | Phase 1 | Hematological Malignancies | — |
| Jun 11 - Jul 23 | HMPL-760 | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — |
| Jul 11 - Aug 22 | Savolitinib | Phase 3 | Non-small Cell Lung Cancer | — |
| Jul 12 - Aug 23 | Nab-paclitaxel Plus Gemcitabine | Phase 3 | Metastatic Pancreatic Cancer | — |
| Aug 7 - Sep 18 | HMPL-A830 | Phase 2 | Solid Tumor, Adult | — |
| Aug 11 - Sep 22 | HMPL-453 | Phase 3 | Advanced Intrahepatic Cholangiocarcinoma; Solid Tumor, Adult | — |
| Jan 11 - Feb 22 | HMPL-A251 | Phase 2 | Solid Tumors, Adult | — |
| Feb 11 - Mar 25 | HMPL-306 Regimen | Phase 3 | Acute Myeloid Leukemia | — |
| Feb 11 - Mar 25 | HMPL-A580 | Phase 2 | Solid Tumors, Adult | — |
| Feb 19 - Apr 2 | fruquintinib | Phase 3 | Advanced Endometrial Cancer | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.